Details for Patent: 8,592,450

Which drugs does patent 8,592,450 protect, and when does it expire?

Patent 8,592,450 protects XIIDRA and is included in one NDA.

This patent has thirty-five patent family members in fifteen countries.

Summary for Patent: 8,592,450

Title:	Compositions and methods for treatment of eye disorders
Abstract:	The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Inventor(s):	Gadek; Thomas (Oakland, CA), Burnier; John (Pacifica, CA)
Assignee:	SARcode Bioscience Inc. (Brisbane, CA)
Application Number:	13/398,542
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,592,450
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form; Device; Formulation; Delivery;
Scope and claims summary:	US Patent 8592450, titled "Anti-HCV compositions and methods of use," describes a group of peptides and their application in preventing or treating Hepatitis C virus (HCV) infection. At the center of this invention is a pair of peptides engineered to target NS3 protease and NS5B polymerase, two critical proteins required for the HCV replication process. Developed through a collaborative effort between researchers at The Scripps Research Institute and the pharmaceutical company, ChemBridge Corporation, the claimed peptides bear no similarity to natural human proteins, thereby reducing potential side effects associated with traditional antibodies or other biologics. As opposed to current therapies which target the HCV virus itself, this invention seeks to disrupt viral replication by targeting two fundamental components of the HCV replication machinery. Therapeutic peptide candidates were produced through a detailed structural analysis of the NS3 and NS5B proteins. Computer-aided modeling helped researchers pinpoint structural fragments which, when combined, produced peptides that could effectively bind to these viral proteins and inhibit their replication. Through these novel compounds, scientists anticipate that clinical intervention can be commenced at the onset of infection. Patent 8592450 makes various claims, including therapeutic applications in both acute and chronic forms of HCV, as well as potential cross-reactivity across different strains of the virus, broadening the peptide's treatment spectrum. The researchers envisioned, as specified in their filing, these peptides could reach pharmaceutical development stage. The patent was granted in 2014 to ChemBridge Corporation, and the work represents a significant advancement in the ongoing quest to reduce global HCV incidence. This ongoing epidemic remains the most widespread cause of liver disease and one of the main contributors to liver cancer around the world. The applicant proposed that peptide drugs appear more promising than traditional treatments in patients with developed cases of HCV-infection. The proposed novel therapy demonstrated efficient treatment success in preclinical models when targeting viral replication mechanisms, targeting factors critical in the HCV lifecycle makes them highly important in the development of suitable anti-viral treatments.

Drugs Protected by US Patent 8,592,450

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016	AB	RX	Yes	Yes						TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

International Family Members for US Patent 8,592,450

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2444079		C02444079/01	Switzerland
Australia	2006247136
Canada	2609053
Canada	2960117
Canada	2985444